Developer docs
API playgroundTry for free, no card

Search company profiles

Crossject

Full company profile

uuid0002aig

Namestring
Crossject
Legal namestring
CROSSJECT SA
Websiteurl
crossject.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Crossject is a French specialty pharmaceutical company headquartered in Dijon, France, that develops and commercializes emergency medicines delivered through its proprietary ZENEO needle-free auto-injector platform. Listed on Euronext Growth Paris since February 2014 under ticker ALCJ, the company targets three core emergency indications: severe allergic reactions (anaphylaxis) via ZENEO Epinephrine, prolonged epileptic seizures via ZEPIZURE (currently under FDA review), and acute adrenal crisis via ET-801. Its addressable patient populations include the approximately 65 million people globally living with epilepsy (40% refractory), the ~5 per 10,000 prevalence of acute adrenal crisis in the US and Europe, and the broad at-risk population for anaphylaxis. The core technology — a needle-free, pre-filled, single-use auto-injector — eliminates needles in time-critical administration, with the company citing speed, reliability, safety, and ease of use as its functional differentiators versus conventional needle-based auto-injectors.

The business model is a platform-plus-products specialty pharma approach: ZENEO serves as the reusable delivery device across multiple drug products, with revenue expected from pharmaceutical product sales once regulatory approvals are secured. ZEPIZURE is being advanced with substantial non-dilutive support from BARDA ($43.3 million funding increase) targeting potential emergency use authorization. The company is preparing for US commercial launch in 2026-2027 and has built US infrastructure including the wholly-owned CROSSJECT USA subsidiary, a VP US Business, a US Chief Medical Officer, and a strategic partnership with Eton Pharmaceuticals for US hospital distribution of ET-801. Additional capital has been raised through €6.9 million France 2030 public funding, €12 million Heights Capital Management bonds, €5.7 million capital increase with Gemmes Venture and Vatel Capital, €5 million Vatel Capital convertible bonds, and a €15 million equity/warrant issuance in June 2026.

As of mid-2025 the company reported 51-100 employees (with 160+ projected through 2026), an H1 2025 net loss of €4.9 million (improved from €6.4 million), and remains pre-commercial with no disclosed product revenue. The company has stated a long-term commercial target of approximately €1 billion in annual sales for ZENEO Epinephrine by 2032, contingent on regulatory approval, commercial launch execution, and US market penetration.

Short descriptiontext

Crossject is a French specialty pharmaceutical company developing needle-free auto-injector (ZENEO) products for emergency medications targeting epileptic seizures, adrenal crisis, and severe allergic reactions, with US commercial launch planned for 2026-2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDijon, France
HQ citystring
Dijon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
needle-free injection, emergency pharmaceuticals, auto-injector devices, drug delivery platform, specialty pharma products
Industry1 code
PRIMARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Specialty Pharmaceutical Drug Delivery Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

CROSSJECT is a specialty pharmaceutical company developing emergency medicines based on its ZENEO needle-free auto-injector platform. The company is working toward regulatory approval and commercial launch, with expected sales of around EUR 1 billion by 2032.

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ZENEO®
Description

Needle-free, pre-filled, single-use auto-injector platform for emergency medication delivery in life-threatening situations including epileptic seizures, adrenal crisis, and allergic shock

crossject.com
+2 more records
Core offering1 text field

Crossject develops and manufactures ZENEO®, a proprietary needle-free, pre-filled, single-use auto-injector platform designed for rapid delivery of emergency medications in life-threatening situations. The company builds a portfolio of emergency pharmaceutical products on top of this platform, including treatments for epileptic seizures, adrenal crises, and severe allergic reactions (anaphylaxis).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Expected sales of around EUR 1 billion by 2032
+1 more record
Product overview1 text field

CROSSJECT is a specialty pharmaceutical company developing emergency medicines based on its ZENEO® needle-free auto-injector platform. The company operates a platform-plus-products model where ZENEO® serves as the core technology enabling needle-free drug delivery across multiple therapeutic applications. The product portfolio includes ZENEO® Epinephrine for severe allergic reactions, ZEPIZURE® for epileptic seizures currently under FDA review, and ET-801 for adrenal insufficiency crises developed through partnership with Eton Pharmaceuticals. The platform is designed to provide safe, reliable, needle-free emergency treatment for life-threatening situations.

Product and service4 records
1ZENEO® Needle-Free Auto-Injector Platform
CategoryDrug Delivery Device Platform
Description

A needle-free, pre-filled, single-use auto-injector platform for rapid, reliable delivery of emergency medications in critical situations, intended for healthcare providers, patients, and emergency responders.

2ZENEO® Epinephrine
CategoryEmergency Pharmaceutical Product
Description

Needle-free epinephrine auto-injector for emergency treatment of severe allergic reactions (anaphylaxis) and allergic shock, enabling immediate administration without a needle.

3ZEPIZURE®
CategoryEmergency Pharmaceutical Product
Description

Emergency medication built on the ZENEO® platform for rapid treatment of prolonged epileptic seizures (including refractory seizures), currently pursuing regulatory approval in the United States.

4ET-801
CategoryEmergency Pharmaceutical Product
Description

Ready-to-use hydrocortisone formulation developed in partnership with Eton Pharmaceuticals for treating adrenal insufficiency crises in the U.S. hospital market.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

CROSSJECT partnered with Eton Pharmaceuticals in March 2025 to develop and commercialize ET-801, a ready-to-use hydrocortisone formulation for treating adrenal insufficiency crises in the US hospital market. The partnership leverages Eton's expertise in the US hospital market for commercial distribution.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

SHL Medical is a leading developer and manufacturer of advanced auto-injector devices used by pharma partners to deliver injectable drugs. It is the most direct comparable to Crossject's ZENEO platform, competing for the same pharmaceutical partnership and combination-product opportunities across emergency and chronic injectable therapies.

TypeDirect peer
Description

Antares Pharma, acquired by Halozyme, pioneered commercial-scale auto-injector technology (Vibex, Sumavel DosePro) used by pharma partners across multiple therapeutic areas. Its device-platform-plus-partner business model closely mirrors Crossject's ZENEO strategy and serves as the most directly comparable public-market benchmark.

TypeDirect peer
Description

Ypsomed is a Swiss-based medical device company specializing in injection and infusion systems, including proprietary auto-injector platforms for pharmaceutical partners. It is a direct platform peer in the device-plus-pharma-partnership model that competes for the same combination-product and self-injection opportunities as Crossject.

TypeBroad incumbent
Description

West Pharmaceutical Services is a global leader in drug delivery components and containment systems, including elastomer components for injectable drug delivery. As a much larger incumbent, it overlaps with Crossject in the injectable drug-delivery supply chain across pharmaceutical customers using auto-injectors, prefilled syringes, and similar combination products.

TypeBroad incumbent
Description

BD is a global medical technology company with a large Medical Delivery Solutions segment covering syringes, needles, and injection devices. While much broader than Crossject, BD operates in the same injection device space and serves overlapping pharmaceutical and emergency-medicine customers with both prefilled syringe and auto-injector offerings.

TypeDirect peer
Description

kaléo manufactures Auvi-Q, a compact epinephrine auto-injector that competes directly in the same anaphylaxis rescue market Crossject is targeting with ZENEO Epinephrine. It is the principal non-EpiPen competitor in US emergency epinephrine and is the most direct commercial competitor for ZENEO Epinephrine.

TypeEmerging player
Description

Emergent BioSolutions develops and supplies emergency medical countermeasures including NARCAN (naloxone) and other acute-care therapeutics. It overlaps with Crossject across the emergency-medicine franchise, biodefense procurement channels (BARDA), and the strategic focus on rapid, single-use rescue therapies.

TypeEmerging player
Description

Adamis Pharmaceuticals (recently acquired by USL) commercialized Symjepi, a pre-filled syringe epinephrine product that competes in the same emergency anaphylaxis category Crossject is targeting. It represents the small-cap, single-product competitor profile with comparable regulatory and US commercialization dynamics.

TypeBroad incumbent
Description

Viatris (formerly Mylan) manufactures EpiPen, the dominant epinephrine auto-injector globally. As the incumbent in Crossject's primary commercial target (anaphylaxis rescue), it defines the market share and pricing environment the ZENEO Epinephrine launch must disrupt.

TypeBroad incumbent
Description

Halozyme Therapeutics acquired Antares Pharma to add a commercial-scale auto-injector platform to its drug-delivery franchise. Its broader ENHANZE drug-delivery technology plus Antares device assets makes it a large-cap public-market comparable for a platform-based, partnership-driven drug delivery strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Crossject

Specialty Pharmaceutical Drug Delivery Devicescrossject.com

Crossject is a French specialty pharmaceutical company developing needle-free auto-injector (ZENEO) products for emergency medications targeting epileptic seizures, adrenal crisis, and severe allergic reactions, with US commercial launch planned for 2026-2027.

What Crossject does

Crossject is a French specialty pharmaceutical company headquartered in Dijon, France, that develops and commercializes emergency medicines delivered through its proprietary ZENEO needle-free auto-injector platform. Listed on Euronext Growth Paris since February 2014 under ticker ALCJ, the company targets three core emergency indications: severe allergic reactions (anaphylaxis) via ZENEO Epinephrine, prolonged epileptic seizures via ZEPIZURE (currently under FDA review), and acute adrenal crisis via ET-801. Its addressable patient populations include the approximately 65 million people globally living with epilepsy (40% refractory), the ~5 per 10,000 prevalence of acute adrenal crisis in the US and Europe, and the broad at-risk population for anaphylaxis. The core technology — a needle-free, pre-filled, single-use auto-injector — eliminates needles in time-critical administration, with the company citing speed, reliability, safety, and ease of use as its functional differentiators versus conventional needle-based auto-injectors.

The business model is a platform-plus-products specialty pharma approach: ZENEO serves as the reusable delivery device across multiple drug products, with revenue expected from pharmaceutical product sales once regulatory approvals are secured. ZEPIZURE is being advanced with substantial non-dilutive support from BARDA ($43.3 million funding increase) targeting potential emergency use authorization. The company is preparing for US commercial launch in 2026-2027 and has built US infrastructure including the wholly-owned CROSSJECT USA subsidiary, a VP US Business, a US Chief Medical Officer, and a strategic partnership with Eton Pharmaceuticals for US hospital distribution of ET-801. Additional capital has been raised through €6.9 million France 2030 public funding, €12 million Heights Capital Management bonds, €5.7 million capital increase with Gemmes Venture and Vatel Capital, €5 million Vatel Capital convertible bonds, and a €15 million equity/warrant issuance in June 2026.

As of mid-2025 the company reported 51-100 employees (with 160+ projected through 2026), an H1 2025 net loss of €4.9 million (improved from €6.4 million), and remains pre-commercial with no disclosed product revenue. The company has stated a long-term commercial target of approximately €1 billion in annual sales for ZENEO Epinephrine by 2032, contingent on regulatory approval, commercial launch execution, and US market penetration.

Crossject firmographics

Firmographics
Name
Crossject
Legal name
CROSSJECT SA
Website
https://crossject.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Crossject is a French specialty pharmaceutical company developing needle-free auto-injector (ZENEO) products for emergency medications targeting epileptic seizures, adrenal crisis, and severe allergic reactions, with US commercial launch planned for 2026-2027.
Ownership category
akta.pro rank

Crossject industry classification

Industry
Product category
Specialty Pharmaceutical Drug Delivery Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Needle-free injection
  • Emergency pharmaceuticals
  • Auto-injector devices
  • Drug delivery platform
  • Specialty pharma products

Where Crossject is headquartered

Location

Headquarters

HQ city
Dijon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Crossject business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: CROSSJECT is a specialty pharmaceutical company developing emergency medicines based on its ZENEO needle-free auto-injector platform. The company is working toward regulatory approval and commercial launch, with expected sales of around EUR 1 billion by 2032.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Crossject product offering

Product offering

Core offering

Crossject develops and manufactures ZENEO®, a proprietary needle-free, pre-filled, single-use auto-injector platform designed for rapid delivery of emergency medications in life-threatening situations. The company builds a portfolio of emergency pharmaceutical products on top of this platform, including treatments for epileptic seizures, adrenal crises, and severe allergic reactions (anaphylaxis).

Product overview

CROSSJECT is a specialty pharmaceutical company developing emergency medicines based on its ZENEO® needle-free auto-injector platform. The company operates a platform-plus-products model where ZENEO® serves as the core technology enabling needle-free drug delivery across multiple therapeutic applications. The product portfolio includes ZENEO® Epinephrine for severe allergic reactions, ZEPIZURE® for epileptic seizures currently under FDA review, and ET-801 for adrenal insufficiency crises developed through partnership with Eton Pharmaceuticals. The platform is designed to provide safe, reliable, needle-free emergency treatment for life-threatening situations.

Differentiator

Problem solved

Functional benefit

Brands

  • ZENEO®: Needle-free, pre-filled, single-use auto-injector platform for emergency medication delivery in life-threatening situations including epileptic seizures, adrenal crisis, and allergic shock
  • ET-801
  • ZEPIZURE®

Products and services

  • ZENEO® Needle-Free Auto-Injector Platform A needle-free, pre-filled, single-use auto-injector platform for rapid, reliable delivery of emergency medications in critical situations, intended for healthcare providers, patients, and emergency responders.
  • ZENEO® Epinephrine Needle-free epinephrine auto-injector for emergency treatment of severe allergic reactions (anaphylaxis) and allergic shock, enabling immediate administration without a needle.
  • ZEPIZURE® Emergency medication built on the ZENEO® platform for rapid treatment of prolonged epileptic seizures (including refractory seizures), currently pursuing regulatory approval in the United States.
  • ET-801 Ready-to-use hydrocortisone formulation developed in partnership with Eton Pharmaceuticals for treating adrenal insufficiency crises in the U.S. hospital market.

Quantifiable outcome

  • Expected sales of around EUR 1 billion by 2032
  • +1 more outcomes

Companies that use Crossject

Customer profile

Segments4 records

Ideal customer profiles3 records

Crossject technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Crossject partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eton PharmaceuticalscoreStrategic or Co-development Partner · 1 March 2025CROSSJECT partnered with Eton Pharmaceuticals in March 2025 to develop and commercialize ET-801, a ready-to-use hydrocortisone formulation for treating adrenal insufficiency crises in the US hospital market. The partnership leverages Eton's expertise in the US hospital market for commercial distribution.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Crossject competitors and assessment

Company assessment

Direct peers

  • SHL Medical: SHL Medical is a leading developer and manufacturer of advanced auto-injector devices used by pharma partners to deliver injectable drugs. It is the most direct comparable to Crossject's ZENEO platform, competing for the same pharmaceutical partnership and combination-product opportunities across emergency and chronic injectable therapies.
  • Antares Pharma (Halozyme): Antares Pharma, acquired by Halozyme, pioneered commercial-scale auto-injector technology (Vibex, Sumavel DosePro) used by pharma partners across multiple therapeutic areas. Its device-platform-plus-partner business model closely mirrors Crossject's ZENEO strategy and serves as the most directly comparable public-market benchmark.
  • Ypsomed: Ypsomed is a Swiss-based medical device company specializing in injection and infusion systems, including proprietary auto-injector platforms for pharmaceutical partners. It is a direct platform peer in the device-plus-pharma-partnership model that competes for the same combination-product and self-injection opportunities as Crossject.
  • kaléo (Auvi-Q): kaléo manufactures Auvi-Q, a compact epinephrine auto-injector that competes directly in the same anaphylaxis rescue market Crossject is targeting with ZENEO Epinephrine. It is the principal non-EpiPen competitor in US emergency epinephrine and is the most direct commercial competitor for ZENEO Epinephrine.

Broad incumbents

  • West Pharmaceutical Services: West Pharmaceutical Services is a global leader in drug delivery components and containment systems, including elastomer components for injectable drug delivery. As a much larger incumbent, it overlaps with Crossject in the injectable drug-delivery supply chain across pharmaceutical customers using auto-injectors, prefilled syringes, and similar combination products.
  • Becton, Dickinson and Company (BD): BD is a global medical technology company with a large Medical Delivery Solutions segment covering syringes, needles, and injection devices. While much broader than Crossject, BD operates in the same injection device space and serves overlapping pharmaceutical and emergency-medicine customers with both prefilled syringe and auto-injector offerings.
  • Viatris (EpiPen): Viatris (formerly Mylan) manufactures EpiPen, the dominant epinephrine auto-injector globally. As the incumbent in Crossject's primary commercial target (anaphylaxis rescue), it defines the market share and pricing environment the ZENEO Epinephrine launch must disrupt.
  • Halozyme Therapeutics: Halozyme Therapeutics acquired Antares Pharma to add a commercial-scale auto-injector platform to its drug-delivery franchise. Its broader ENHANZE drug-delivery technology plus Antares device assets makes it a large-cap public-market comparable for a platform-based, partnership-driven drug delivery strategy.

Emerging players

  • Emergent BioSolutions: Emergent BioSolutions develops and supplies emergency medical countermeasures including NARCAN (naloxone) and other acute-care therapeutics. It overlaps with Crossject across the emergency-medicine franchise, biodefense procurement channels (BARDA), and the strategic focus on rapid, single-use rescue therapies.
  • Adamis Pharmaceuticals (USL): Adamis Pharmaceuticals (recently acquired by USL) commercialized Symjepi, a pre-filled syringe epinephrine product that competes in the same emergency anaphylaxis category Crossject is targeting. It represents the small-cap, single-product competitor profile with comparable regulatory and US commercialization dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Crossject social profiles

Digital presence

Crossject financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Crossject leadership team

Management profile

Number of profiles

Profiles12 records

Crossject subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Crossject funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Crossject M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crossject

What does Crossject do?

Crossject develops and manufactures ZENEO®, a proprietary needle-free, pre-filled, single-use auto-injector platform designed for rapid delivery of emergency medications in life-threatening situations. The company builds a portfolio of emergency pharmaceutical products on top of this platform, including treatments for epileptic seizures, adrenal crises, and severe allergic reactions (anaphylaxis).

Is Crossject a public or private company?

Crossject is a public company. It is classified as public and is currently operating.

When was Crossject founded?

Crossject was founded in 2014. It employs 51 to 100 people.

Where is Crossject based?

Crossject is headquartered in Dijon, France, in the Europe region.

How does Crossject make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Crossject's main competitors?

Direct peers on record are SHL Medical, Antares Pharma (Halozyme), Ypsomed and kaléo (Auvi-Q). Broad incumbents are West Pharmaceutical Services, Becton, Dickinson and Company (BD), Viatris (EpiPen) and Halozyme Therapeutics. Emerging players are Emergent BioSolutions and Adamis Pharmaceuticals (USL).

Does Crossject have an API?

No public API is recorded for Crossject.

What industry is Crossject in?

Crossject's product category is Specialty Pharmaceutical Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingCrossject gains analyst coverage as Portzamparc initiates on stockPortzamparc initiated coverage of Crossject in February 2026. The stock is now covered by five research firms: Alpha Value, Invest Securities, Maxim Group, ODDO BHF, and Portzamparc.The future of tradingCrossject expands executive board to five with Lacombe, Morin, Seltz appointmentsCrossject expanded its executive board to five members, appointing Olivier Lacombe, Didier Morin, and Lionel Seltz with immediate effect. Lacombe brings 21 years in pharmaceutical development, Morin 30 in industrial operations, and Seltz 25 in life sciences finance. The company also appointed David Pudwill as VP of Regulatory & Scientific Affairs.The future of tradingCrossject H1 FY26 net loss widens to €8.6 million; revenue falls 40% to €4.8 millionCrossject reported H1 FY26 revenue of €4.8 million, down 40% year over year, and a net loss of €8.6 million, up from €4.9 million. Cash rose to €12.3 million at June 30, more than doubled from year-end, following a €15 million capital increase. The company said its focus remains on ZEPIZURE registration and preparing first shipments.The future of tradingCROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial StructureCROSSJECT reported H1 2026 results, showing cash of €12.3 million and positive equity of €3.0 million after a €15 million capital increase. BARDA revenue fell to €2.5 million from €6.6 million, and net income was −€8.6 million. The BARDA contract was extended to 2030 with additional funding.The future of tradingCROSSJECT strengthens its governance for the industrial and commercial deployment phaseCROSSJECT expanded its Executive Board to five members, adding Olivier Lacombe, Didier Morin, and Lionel Seltz, effective immediately. The company also appointed David Pudwill as Vice President of Regulatory & Scientific Affairs for its U.S. entity. The moves support industrialization and commercialization of its ZENEO-based products.YahooCROSSJECT strengthens its governance for the industrial and commercial deployment phaseCROSSJECT expanded its Executive Board to five members, adding Olivier Lacombe, Didier Morin, and Lionel Seltz, effective immediately. The company also appointed David Pudwill as Vice President of Regulatory & Scientific Affairs at CROSSJECT US. The changes support the industrialization and U.S. commercialization of its ZENEO-based products.YahooCROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial StructureCROSSJECT reported H1 2026 results with cash of €12.3 million and positive equity of €3.0 million, after a €15 million capital increase. BARDA revenue fell to €2.5 million from €6.6 million, and net income was −€8.6 million. The BARDA contract was extended to 2030 with additional funding.The future of tradingCrossject secures USD 4.7 million BARDA funding for Zepizure pediatric development plan through 2030Crossject secured $4.7 million in additional BARDA funding for Zepizure pediatric development, extending the contract through June 21, 2030. Total BARDA support for Zepizure rises to $48 million. The adult Emergency Use Authorization filing remains unchanged.YahooCROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030CROSSJECT and BARDA aligned the pediatric development plan for ZEPIZURE with FDA guidance, adding $4.7 million in non-dilutive funding and extending the contract through June 21, 2030. Total BARDA funding for ZEPIZURE now stands at $48.0 million, with the adult EUA pathway unchanged.Simply Wall StCrossject Société Anonyme (EPA:ALCJ) On The Verge Of Breaking EvenCrossject Soci\u00e9t\u00e9 Anonyme, a French needle-free injection systems developer with a \u20ac91m market cap, reported a \u20ac10m loss for its most recent financial year ending 31 December 2025. Two French medical equipment analysts expect a final 2025 loss followed by \u20ac28m in 2026 profits, implying breakeven within 12 months. The company carries negative equity on its balance sheet.